Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
GBM
Advertisement
BioLineRx and Hemispherian Present GLIX1 Data
Tel Aviv, Israel, and Oslo, Norway, September 10, 2026 BioLineRx Ltd. and Hemispherian AS have announced that two abstracts...
Northwest Biotherapeutics Partners with SPIMACO to Advance DCVax-L in Saudi Arabia
BETHESDA, Md., August 6, 2026 Northwest Biotherapeutics announced that it has entered into a non-binding Memorandum of Understanding (MOU)...
Laminar Completes CLINGLIO Trial Enrollment for LAM561
MALLORCA, Spain, July 23, 2026 Laminar Pharmaceuticals S.A. has announced the successful completion of patient recruitment for the CLINGLIO...
IN8bio Publishes Positive Phase 1 GBM Data
NEW YORK, July 9, 2026 IN8bio announced the publication of peer-reviewed Phase 1 clinical trial results for its investigational...
Advertisements
Northwest Biotherapeutics to Present DCVax-L Survival Analysis at BNOS 2026
BETHESDA, Md., July 2, 2026 Northwest Biotherapeutics announced that its Chief Technical Officer, Dr. Marnix Bosch, will deliver a...
Novocure Reports Phase 3 TRIDENT Trial Results
BAAR, Switzerland | June 18, 2026 Novocure has announced topline results from its Phase 3 TRIDENT trial, which evaluated...
Trogenix Doses First Patient in TGX-007 Glioblastoma Trial
Edinburgh, UK | May 28, 2026 Clinical-stage oncology company Trogenix announced the first patient has been dosed in the...
BioLineRx and Hemispherian Showcase GLIX1 Cancer Data at ASCO 2026
Tel Aviv, Israel and Oslo, Norway – May 22, 2026 BioLineRx Ltd. and Hemispherian AS announced new preclinical and...
Sapience Reports Positive Glioblastoma Trial Data
TARRYTOWN, N.Y., May 21, 2026 Sapience Therapeutics has announced encouraging updated clinical data from its ongoing Phase 2 trial...
Advertisement
